GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Beneish M-Score

Akoya Biosciences (Akoya Biosciences) Beneish M-Score : -2.77 (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.77 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Akoya Biosciences's Beneish M-Score or its related term are showing as below:

AKYA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.27   Med: -2.78   Max: -2.08
Current: -2.77

During the past 5 years, the highest Beneish M-Score of Akoya Biosciences was -2.08. The lowest was -3.27. And the median was -2.78.


Akoya Biosciences Beneish M-Score Historical Data

The historical data trend for Akoya Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences Beneish M-Score Chart

Akoya Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -2.39 -3.03 -2.22

Akoya Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.00 -2.84 -2.24 -2.22 -2.77

Competitive Comparison of Akoya Biosciences's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akoya Biosciences's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's Beneish M-Score falls into.



Akoya Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Akoya Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.883+0.528 * 1.0258+0.404 * 0.907+0.892 * 1.1789+0.115 * 0.725
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8072+4.679 * -0.062216-0.327 * 1.093
=-2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $13.47 Mil.
Revenue was 18.35 + 26.487 + 25.215 + 23.521 = $93.57 Mil.
Gross Profit was 8.379 + 16.62 + 15.276 + 12.116 = $52.39 Mil.
Total Current Assets was $101.83 Mil.
Total Assets was $154.75 Mil.
Property, Plant and Equipment(Net PPE) was $15.88 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.82 Mil.
Selling, General, & Admin. Expense(SGA) was $80.49 Mil.
Total Current Liabilities was $33.19 Mil.
Long-Term Debt & Capital Lease Obligation was $81.82 Mil.
Net Income was -23.484 + -10.802 + -12.916 + -20.803 = $-68.01 Mil.
Non Operating Income was -4.708 + -0.622 + -0.447 + -0.635 = $-6.41 Mil.
Cash Flow from Operations was -20.824 + -5.584 + -13.753 + -11.804 = $-51.97 Mil.
Total Receivables was $12.94 Mil.
Revenue was 21.41 + 21.219 + 18.852 + 17.894 = $79.38 Mil.
Gross Profit was 12.293 + 12.046 + 10.907 + 10.341 = $45.59 Mil.
Total Current Assets was $91.67 Mil.
Total Assets was $154.30 Mil.
Property, Plant and Equipment(Net PPE) was $21.90 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.65 Mil.
Selling, General, & Admin. Expense(SGA) was $84.58 Mil.
Total Current Liabilities was $33.22 Mil.
Long-Term Debt & Capital Lease Obligation was $71.69 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(13.473 / 93.573) / (12.943 / 79.375)
=0.143984 / 0.163061
=0.883

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(45.587 / 79.375) / (52.391 / 93.573)
=0.574324 / 0.559894
=1.0258

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (101.829 + 15.88) / 154.75) / (1 - (91.674 + 21.902) / 154.297)
=0.23936 / 0.263913
=0.907

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=93.573 / 79.375
=1.1789

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7.651 / (7.651 + 21.902)) / (8.82 / (8.82 + 15.88))
=0.258891 / 0.357085
=0.725

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(80.486 / 93.573) / (84.584 / 79.375)
=0.860141 / 1.065625
=0.8072

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((81.816 + 33.193) / 154.75) / ((71.692 + 33.223) / 154.297)
=0.743192 / 0.679955
=1.093

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-68.005 - -6.412 - -51.965) / 154.75
=-0.062216

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Akoya Biosciences has a M-score of -2.77 suggests that the company is unlikely to be a manipulator.


Akoya Biosciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Akoya Biosciences (Akoya Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.
Executives
Brian Mckelligon director, officer: President/CEO 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla officer: Chief Operating Officer C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler director C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin director, 10 percent owner C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler director
Jennifer Kamocsay officer: General Counsel 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll officer: Chief Financial Officer 5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d. director 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry officer: Chief Medical Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy officer: Chief People Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d officer: Chief Business Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752

Akoya Biosciences (Akoya Biosciences) Headlines